<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1014">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04551898</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-DXP593-102</org_study_id>
    <nct_id>NCT04551898</nct_id>
  </id_info>
  <brief_title>Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Patients WithMild-to-Moderate COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to investigate the safety and tolerability of
      BGB-DXP593 administered intravenously as a single dose in participants with mild-to-moderate
      COVID-19.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 30, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to Day 8 in SARS-CoV-2 viral shedding as measured by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal swab samples</measure>
    <time_frame>Up to 8 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-weighted average change in viral shedding as measured by RT-qPCR in nasopharyngeal swab samples</measure>
    <time_frame>Baseline to Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Day 15 in SARS-CoV-2 viral shedding as measured by RT-qPCR in nasopharyngeal swab samples</measure>
    <time_frame>Baseline to Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to negative RT-qPCR in all tested samples with no subsequent positive RT-qPCR in any tested samples</measure>
    <time_frame>Up to 15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants requiring hospitalization due to worsened COVID-19</measure>
    <time_frame>Up to 29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of all COVID-19-related symptoms</measure>
    <time_frame>Up to 29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality rate at Day 29</measure>
    <time_frame>Up to 29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing Adverse Events (AEs)</measure>
    <time_frame>Up to 85 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 85 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>BGB-DXP593 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive BGB-DXP593 on Day 1, and followed up for safety for up to 85 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BGB-DXP593 Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive BGB-DXP593 on Day 1, and followed up for safety for up to 85 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BGB-DXP593 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive BGB-DXP593 on Day 1, and followed up for safety for up to 85 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo on Day 1, and followed up for safety for up to 85 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-DXP593</intervention_name>
    <description>Intravenous (IV) infusion administered over 30 to 60 minutes at a dose as specified in the treatment arm</description>
    <arm_group_label>BGB-DXP593 High Dose</arm_group_label>
    <arm_group_label>BGB-DXP593 Low Dose</arm_group_label>
    <arm_group_label>BGB-DXP593 Medium Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match BGB-DXP593 administered as specified in the treatment arm</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Laboratory-confirmed severe acute respiratory syndrome (SARS)-CoV-2 infection
             (positive reverse transcription-polymerase chain reaction [RT-PCR] test or other
             authorized antigen testing methods) in any samples following local practice ≤ 72 hours
             prior to screening.

          2. Have experienced COVID-19 symptoms for ≤ 7 days prior to treatment assignment, such as
             fever, cough, shortness of breath, sore throat, diarrhea, vomiting, and dysgeusia

          3. Agree to the collection of nasopharyngeal swabs, saliva, and venous blood

        Key Exclusion Criteria:

          1. Severe COVID-19 having oxygen saturation (SpO2) ≤ 93 % on room air at sea level or
             ratio of arterial oxygen partial pressure (PaO2 in millimeters of mercury) to
             fractional inspired oxygen (FiO2) &lt; 300, respiratory rate ≥ 30/min, heart rate ≥
             125/min

          2. Requires mechanical ventilation or anticipated impending need for mechanical
             ventilation

          3. Known allergies to any of the components used in the formulation of the interventions

          4. Have received an investigational intervention for SARS-CoV-2 prophylaxis within 30
             days before dosing

          5. Have received treatment with a SARS-CoV-2 specific monoclonal antibody

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhen Yao, MD</last_name>
    <role>Study Director</role>
    <affiliation>BeiGene</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BeiGene</last_name>
    <phone>+1-877-828-5568</phone>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 10, 2020</study_first_submitted>
  <study_first_submitted_qc>September 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2020</study_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

